IL303767A - Pharmaceutical formulations of centrapadin, and methods for its preparation and use - Google Patents

Pharmaceutical formulations of centrapadin, and methods for its preparation and use

Info

Publication number
IL303767A
IL303767A IL303767A IL30376723A IL303767A IL 303767 A IL303767 A IL 303767A IL 303767 A IL303767 A IL 303767A IL 30376723 A IL30376723 A IL 30376723A IL 303767 A IL303767 A IL 303767A
Authority
IL
Israel
Prior art keywords
pharmaceutical formulation
beads
ctn
range
formulation
Prior art date
Application number
IL303767A
Other languages
English (en)
Hebrew (he)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of IL303767A publication Critical patent/IL303767A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL303767A 2021-02-23 2022-02-22 Pharmaceutical formulations of centrapadin, and methods for its preparation and use IL303767A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152826P 2021-02-23 2021-02-23
US202163241839P 2021-09-08 2021-09-08
PCT/JP2022/007314 WO2022181625A1 (en) 2021-02-23 2022-02-22 Centanafadine pharmaceutical formulations, and methods of making and using same

Publications (1)

Publication Number Publication Date
IL303767A true IL303767A (en) 2023-08-01

Family

ID=80735736

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303767A IL303767A (en) 2021-02-23 2022-02-22 Pharmaceutical formulations of centrapadin, and methods for its preparation and use

Country Status (11)

Country Link
US (6) US11564885B2 (enExample)
EP (1) EP4297734A1 (enExample)
JP (2) JP7787190B2 (enExample)
KR (1) KR20230152046A (enExample)
AU (1) AU2022227367A1 (enExample)
BR (1) BR112023015272A2 (enExample)
CA (1) CA3205786A1 (enExample)
IL (1) IL303767A (enExample)
MX (1) MX2023009833A (enExample)
TW (1) TW202302086A (enExample)
WO (1) WO2022181625A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023015272A2 (pt) * 2021-02-23 2023-11-07 Otsuka Pharma Co Ltd Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
KR20250053128A (ko) * 2022-08-24 2025-04-21 오츠카 세이야쿠 가부시키가이샤 센타나파딘을 포함하는 제약 조성물
US20250375418A1 (en) * 2022-09-02 2025-12-11 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder
WO2025183181A1 (en) 2024-02-28 2025-09-04 Otsuka Pharmaceutical Co., Ltd. Use of centanafadine in treatment of adhd symptoms
US12502358B1 (en) 2024-08-13 2025-12-23 Innovate Therapeutics Llc Centanafadine multiphasic controlled-release pharmaceutical formulation
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006133349A2 (en) 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
EP1915146A4 (en) * 2005-07-27 2010-06-02 Dov Pharmaceutical Inc NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES
ES2529455T3 (es) * 2006-05-12 2015-02-20 Shire Llc Sistema de administración de fármacos por dosis controladas
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US20140206740A1 (en) * 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN107335057A (zh) 2012-07-27 2017-11-10 韦尔斯利医药有限公司 用于缓解尿频的药物制剂及其使用方法
CN106029637A (zh) 2013-12-09 2016-10-12 纽罗万斯公司 新的组合物
EP3069715A1 (en) * 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
US20180008575A1 (en) 2016-07-11 2018-01-11 Neurovance, Inc. Methods of treating binge eating disorder
BR112023015272A2 (pt) * 2021-02-23 2023-11-07 Otsuka Pharma Co Ltd Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas

Also Published As

Publication number Publication date
AU2022227367A1 (en) 2023-08-03
US20250041225A1 (en) 2025-02-06
US11564885B2 (en) 2023-01-31
US20230338293A1 (en) 2023-10-26
JP7787190B2 (ja) 2025-12-16
MX2023009833A (es) 2023-09-04
TW202302086A (zh) 2023-01-16
US20240165030A1 (en) 2024-05-23
JP2024506595A (ja) 2024-02-14
EP4297734A1 (en) 2024-01-03
US11980690B2 (en) 2024-05-14
US12156941B2 (en) 2024-12-03
AU2022227367A9 (en) 2024-10-17
US11759426B2 (en) 2023-09-19
JP2025183214A (ja) 2025-12-16
US20250319030A1 (en) 2025-10-16
US20220265557A1 (en) 2022-08-25
BR112023015272A2 (pt) 2023-11-07
CA3205786A1 (en) 2022-09-01
WO2022181625A1 (en) 2022-09-01
US12370144B2 (en) 2025-07-29
US20230104529A1 (en) 2023-04-06
KR20230152046A (ko) 2023-11-02

Similar Documents

Publication Publication Date Title
IL303767A (en) Pharmaceutical formulations of centrapadin, and methods for its preparation and use
US20200000726A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
US5807579A (en) Pseudoephedrine combination pharmaceutical compositions
AU2007267159B2 (en) Lipoic acid pellets
JPH02240017A (ja) 放出性が改良されたジエムフイブロジル組成物
US20130064888A1 (en) Pharmaceutical formulations
SK175997A3 (en) Controlled release formulations for poorly soluble drugs
JP2024506595A5 (enExample)
EP2740471B1 (en) Oral pharmaceutical composition comprising dabigatran etexilate
US20080206335A1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
CA2374039C (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
US20090264408A1 (en) Extended release dosage forms of quetiapine
US20220273619A1 (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolylglycyl-l-tyrosinate and methods for preparing the same
US10098898B1 (en) Release stable mesalamine dosage forms
CN115737597A (zh) 一种口服的肠溶速释药物组合物、制备方法及其应用
JP6626492B2 (ja) コハク酸メトプロロールのカプセル剤形
US20090214665A1 (en) Controlled Release Muscarinic Receptor Antagonist Formulation
WO2021101481A1 (en) A pellet composition comprising propiverine or a pharmaceutically acceptable salt thereof
AU2016255302B2 (en) Rivastigmine-containing sustained-release pharmaceutical composition
CA3064891A1 (en) Delayed sustained release pharmaceutical compositions
KR101118866B1 (ko) 박동성 방출 제제 및 그 제조방법
JP2008174481A (ja) テオフィリン含有コーティング顆粒
WO2024162929A1 (en) A controlled release formulation of propiverine
US20150209292A1 (en) Controlled release formulations and preparation method thereof
WO2013013798A1 (en) Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof